Cutera (CUTR) Downgraded by Zacks Investment Research to “Sell”

Cutera (NASDAQ:CUTR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

A number of other analysts have also recently commented on the company. ValuEngine cut Cutera from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. BidaskClub upgraded Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. TheStreet cut Cutera from a “c” rating to a “d” rating in a research report on Thursday, February 21st. Stephens reduced their price objective on Cutera from $40.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, February 21st. They noted that the move was a valuation call. Finally, Maxim Group reiterated a “hold” rating on shares of Cutera in a research report on Monday, February 11th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $34.67.

Cutera stock traded up $0.03 during mid-day trading on Wednesday, reaching $17.49. 78,619 shares of the stock traded hands, compared to its average volume of 210,646. The stock has a market cap of $235.96 million, a PE ratio of -7.84 and a beta of 0.71. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.09 and a current ratio of 1.66. Cutera has a 12-month low of $12.32 and a 12-month high of $48.85.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Thursday, May 9th. The medical device company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.30). The firm had revenue of $36.00 million for the quarter, compared to analysts’ expectations of $33.45 million. Cutera had a negative net margin of 22.45% and a negative return on equity of 65.62%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.02) EPS. As a group, sell-side analysts predict that Cutera will post -0.33 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its position in Cutera by 0.3% in the first quarter. BlackRock Inc. now owns 2,017,255 shares of the medical device company’s stock worth $35,625,000 after buying an additional 5,170 shares in the last quarter. Gamco Investors INC. ET AL lifted its holdings in Cutera by 11.4% in the first quarter. Gamco Investors INC. ET AL now owns 1,100,801 shares of the medical device company’s stock valued at $19,440,000 after acquiring an additional 112,800 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its holdings in Cutera by 96.4% in the first quarter. Paradigm Capital Management Inc. NY now owns 834,500 shares of the medical device company’s stock valued at $14,737,000 after acquiring an additional 409,700 shares during the last quarter. Gabelli Funds LLC raised its position in Cutera by 5.6% in the first quarter. Gabelli Funds LLC now owns 644,807 shares of the medical device company’s stock valued at $11,387,000 after purchasing an additional 34,400 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Cutera by 12.6% in the first quarter. Dimensional Fund Advisors LP now owns 618,504 shares of the medical device company’s stock valued at $10,923,000 after purchasing an additional 69,026 shares during the period. Institutional investors and hedge funds own 91.50% of the company’s stock.

About Cutera

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Read More: Cost of Debt

Get a free copy of the Zacks research report on Cutera (CUTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.